Record-Setting Deal For Pharmasset Expected To Boost Value Of Other HCV Biotechs
By
Joseph Haas / Email the Author / “The Pink Sheet” Nov. 28, 2011, Vol. 73, No. 48
Business & Finance / Word Count: 1347 / Article # 00111128014
Executive Summary
The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.